Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

Wilton B. Williams(Duke University), Hua-Xin Liao(Duke University), M. Anthony Moody(Duke University), Thomas B. Kepler(Boston University), S. Munir Alam(Duke University), Feng Gao(Duke University), Kevin Wiehe(Duke University), Ashley M. Trama(Duke University), Kathryn Jones(Duke University), Ruijun Zhang(Duke University), Hongshuo Song(Duke University), Dawn J. Marshall(Duke University), John F. Whitesides(Duke University), Kaitlin Sawatzki(Boston University), Axin Hua(Boston University), Pinghuang Liu(Duke University), Matthew Zirui Tay(Duke University), Kelly E. Seaton(Duke University), Xiaoying Shen(Duke University), Andrew Foulger(Duke University), Krissey E. Lloyd(Duke University), Robert Parks(Duke University), Justin Pollara(Duke University), Guido Ferrari(Duke University), Jae-Sung Yu(Duke University), Nathan Vandergrift(Duke University), David C. Montefiori(Duke University), Magdalena E. Sobieszczyk(Columbia University Irving Medical Center), Scott Hammer(Columbia University Irving Medical Center), Shelly Karuna(Fred Hutch Cancer Center), Peter B. Gilbert(Fred Hutch Cancer Center), Doug Grove(Fred Hutch Cancer Center), Nicole Grunenberg(Fred Hutch Cancer Center), M. Juliana McElrath(Fred Hutch Cancer Center), John R. Mascola(National Institutes of Health), Richard A. Koup(National Institutes of Health), Lawrence Corey(Fred Hutch Cancer Center), Gary J. Nabel(National Institutes of Health), Cecilia Morgan(Fred Hutch Cancer Center), Gavin Churchyard(Aurum Institute), Janine Maenza(Fred Hutch Cancer Center), Michael C. Keefer(University of Rochester), Barney S. Graham(National Institutes of Health), Lindsey R. Baden(Brigham and Women's Hospital), Georgia D. Tomaras(Duke University), Barton F. Haynes(Duke University)
Science
July 31, 2015
Cited by 202

Abstract

An HIV-1 DNA prime vaccine, with a recombinant adenovirus type 5 (rAd5) boost, failed to protect from HIV-1 acquisition. We studied the nature of the vaccine-induced antibody (Ab) response to HIV-1 envelope (Env). HIV-1-reactive plasma Ab titers were higher to Env gp41 than to gp120, and repertoire analysis demonstrated that 93% of HIV-1-reactive Abs from memory B cells responded to Env gp41. Vaccine-induced gp41-reactive monoclonal antibodies were non-neutralizing and frequently polyreactive with host and environmental antigens, including intestinal microbiota (IM). Next-generation sequencing of an immunoglobulin heavy chain variable region repertoire before vaccination revealed an Env-IM cross-reactive Ab that was clonally related to a subsequent vaccine-induced gp41-reactive Ab. Thus, HIV-1 Env DNA-rAd5 vaccine induced a dominant IM-polyreactive, non-neutralizing gp41-reactive Ab repertoire response that was associated with no vaccine efficacy.


Related Papers

No related papers found

Powered by citation graph analysis